Literature DB >> 15682697

The financial impact of controlling a respiratory virus outbreak in a teaching hospital: lessons learned from SARS.

Camille Achonu1, Audrey Laporte, Michael A Gardam.   

Abstract

BACKGROUND: Outbreaks of Severe Acute Respiratory Syndrome (SARS) in 2003 and renewed concerns regarding pandemic influenza have resulted in widespread planning for future respiratory disease outbreaks. Such planning should include accurate cost estimates for any proposed disease control strategies. From the acute care hospital perspective, such estimates typically take into account the cost of supplies and equipment, but rarely consider indirect costs such as lost revenue due to the scaling down of programs.
METHODS: Retrospective cost analysis. Costs and savings were calculated from the hospital perspective using financial records. Costs were categorized to determine the major areas of expenditure and savings.
RESULTS: We report that controlling a SARS outbreak in a teaching hospital over an 8-week period cost dollar12 million Canadian. Lost revenue and labour accounted for two thirds of the costs incurred while excess spending on services, materials, supplies and renovation of existing space accounted for the remaining one third.
CONCLUSIONS: Cost estimates that consider only excess expenditures may considerably underestimate the true cost of infection control strategies.

Entities:  

Mesh:

Year:  2005        PMID: 15682697

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  14 in total

1.  Enhanced viral etiological diagnosis of respiratory system infection outbreaks by use of a multitarget nucleic acid amplification assay.

Authors:  Sallene Wong; Kanti Pabbaraju; Bonita E Lee; Julie D Fox
Journal:  J Clin Microbiol       Date:  2009-10-14       Impact factor: 5.948

2.  Forecasting Models for Coronavirus Disease (COVID-19): A Survey of the State-of-the-Art.

Authors:  Gitanjali R Shinde; Asmita B Kalamkar; Parikshit N Mahalle; Nilanjan Dey; Jyotismita Chaki; Aboul Ella Hassanien
Journal:  SN Comput Sci       Date:  2020-06-11

Review 3.  Middle East respiratory syndrome: obstacles and prospects for vaccine development.

Authors:  Amy B Papaneri; Reed F Johnson; Jiro Wada; Laura Bollinger; Peter B Jahrling; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2015-04-11       Impact factor: 5.217

Review 4.  Collateral damage: the unforeseen effects of emergency outbreak policies.

Authors:  Sue Lim; Tom Closson; Gillian Howard; Michael Gardam
Journal:  Lancet Infect Dis       Date:  2004-11       Impact factor: 25.071

Review 5.  Emerging viruses: coming in on a wrinkled wing and a prayer.

Authors:  Kim Halpin; Alexander D Hyatt; Raina K Plowright; Jonathan H Epstein; Peter Daszak; Hume E Field; Linfa Wang; Peter W Daniels
Journal:  Clin Infect Dis       Date:  2007-01-23       Impact factor: 9.079

6.  The French Infectious Diseases Society's readiness and response to epidemic or biological risk-the current situation following the Middle East respiratory syndrome coronavirus and Ebola virus disease alerts.

Authors:  H Coignard-Biehler; C Rapp; J M Chapplain; B Hoen; D Che; P Berthelot; F Cazenave-Roblot; C Rabaud; P Brouqui; C Leport
Journal:  Med Mal Infect       Date:  2017-11-21       Impact factor: 2.152

7.  People's perception and cost-effectiveness of home confinement during an influenza pandemic: evidence from the French case.

Authors:  Caroline Orset
Journal:  Eur J Health Econ       Date:  2018-04-23

8.  Studies on membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein.

Authors:  Daniel Voss; Susanne Pfefferle; Christian Drosten; Lea Stevermann; Elisabetta Traggiai; Antonio Lanzavecchia; Stephan Becker
Journal:  Virol J       Date:  2009-06-18       Impact factor: 4.099

Review 9.  Clinical and economical impact of multiplex respiratory virus assays.

Authors:  Emilie Vallières; Christian Renaud
Journal:  Diagn Microbiol Infect Dis       Date:  2013-04-17       Impact factor: 2.803

Review 10.  Respiratory virus surveillance and outbreak investigation.

Authors:  Julie D Fox
Journal:  J Clin Virol       Date:  2007-11       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.